Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis

Lara Paracchini, MSc; Chiara Pesenti, MSc; Martina Delle Marchette, MD; Luca Beltrame, PhD; Tommaso Bianchi, MD; Tommaso Grassi, MD; Alessandro Buda, MD; Fabio Landoni, MD; Lorenzo Ceppi, MD; Cristina Bosetti, PhD; Mariachiara Paderno, MD; Marco Adorni, MD; Debora Vicini, MD; Patrizia Perego, MD; Biagio Eugenio Leone, MD; Maurizio D’Incalci, MD; Sergio Marchini, PhD; Robert Fruscio, MD, PhD

Abstract

IMPORTANCE The low 5-year survival rate of women with high-grade serous epithelial ovarian cancer (HGS-EOC) is related to its late diagnosis; thus, improvement in diagnosis constitutes a crucial step to increase the curability of this disease.

OBJECTIVE To determine whether the presence of the clonal pathogenic TP53 variant detected in matched primary tumor biopsies can be identified in DNA purified from Papanicolaou test samples collected from women with HGS-EOC years before the diagnosis.

DESIGN, SETTING, AND PARTICIPANTS This cohort study was conducted among a single-center cohort of women with histologically confirmed diagnosis of HGS-EOC recruited at San Gerardo Hospital, Monza, Italy, from October 15, 2015, to January 4, 2019. Serial dilutions of DNA derived from tumor samples and DNA extracted from healthy women’s Papanicolaou test samples were analyzed to define the sensitivity and specificity of droplet digital polymerase chain reaction assays designed to detect the TP53 variants identified in tumors. All available brush-based Papanicolaou test slides performed up to 6 years before diagnosis were investigated at the Mario Negri Institute, Milano, Italy. Data were analyzed from October 2018 to December 2019.

MAIN OUTCOMES AND MEASURES The presence of tumor pathogenic TP53 variants was assessed by the droplet digital polymerase chain reaction approach in DNA purified from Papanicolaou test samples obtained from the same patients before diagnosis during cervical cancer screenings.

RESULTS Among 17 included patients (median [interquartile range] age at diagnosis, 60 [53-69] years), Papanicolaou tests withdrawn before diagnosis presented tumor-matched TP53 variants in 11 patients (64%). In 2 patients for whom longitudinal Papanicolaou tests were available, including 1 patient with Papanicolaou tests from 25 and 49 months before diagnosis and 1 patient with Papanicolaou tests from 27 and 68 months before diagnosis, the TP53 clonal variant was detected at all time points.

CONCLUSIONS AND RELEVANCE These findings suggest that noninvasive early molecular diagnosis of HGS-EOC is potentially achievable through detection of TP53 clonal variants in the DNA purified from Papanicolaou tests performed during cervical cancer screening.

JAMA Network Open. 2020;3(7):e207566. doi:10.1001/jamanetworkopen.2020.7566
Introduction

High-grade serous epithelial ovarian cancer (HGS-EOC) is characterized by a clonal pathogenic variant in the TP53 (OMIM 191170) gene, which represents one of the early events in the etiopathogenetic process. It has been demonstrated that the same TP53 clonal variant detected in the primary tumor site can also be detected in precancerous lesions in the Fallopian tube, known as serous tubal intraepithelial carcinomas. Recently, early serous proliferations in the Fallopian tube were found to share the same TP53 variant identified in concurrent metastatic HGS-EOCs, even in the absence of a detectable serous tubal intraepithelial carcinomas. A mathematical model based on a lesion-specific proliferation rate suggests that serous tubal intraepithelial carcinomas progression to carcinoma takes approximately 6 years. To our knowledge, experimental evidence in support of this theoretical prediction is lacking, which hampers the potential development of a test for the early diagnosis of ovarian cancer.

Clonal pathogenic variants in the TP53 gene are suitable candidates to identify early steps in the neoplastic transformation toward HGS-EOC at the molecular level. Recently, several studies have shown the feasibility of detecting somatic variants in DNA from endometrial and ovarian cancers retrieved from various types of vaginal samples collected at the time of diagnosis. The aim of this study was to explore the possibility of exploiting the Papanicolaou test conducted for cervical cancer screening years before diagnosis as a source of material to detect clonal variants in the TP53 gene as a basis to develop assays for the early diagnosis of HGS-EOC.

Methods

This study was approved by the ethics committee of San Gerardo Hospital, Monza, Italy. All participants provided signed informed consent, and participants did not receive any financial compensation. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

Women with histologically confirmed stage II through IV HGS-EOC were selected from a collection of patients with HGS-EOC who underwent primary surgical treatment at the San Gerardo Hospital from October 15, 2015, to January 4, 2019. As described in the Figure, women were selected on the basis of the availability of primary tumor formalin-fixed paraffin-embedded slides and matched brush-based Papanicolaou test slides routinely withdrawn during cervical cancer screenings performed at different time points before diagnosis (up to 6 years) and cytologically negative for dysplasia or any other malignant neoplasms.

Figure. Study Flow Diagram

For each locus-specific TP53 variant assay, droplet digital polymerase chain reaction experiments were performed with both positive and negative controls. Assay sensitivity was assessed on DNA purified from healthy donors. FFPE indicates formalin-fixed paraffin-embedded and HGS-EOC, high-grade serous epithelial ovarian cancer.
To identify the somatic clonal pathogenic TP53 variants in primary tumor biopsies, DNA was purified from formalin-fixed paraffin-embedded samples (eAppendix 1 and eFigure in the Supplement) and was analyzed by next generation sequencing (NGS) technology following manufacturer’s instructions. Briefly, NGS libraries were prepared starting from 100 ng of tumor DNA, using a capture-based custom panel of probes that covers the exons of the TP53 gene (SeqCap EZ Target Enrichment System, Roche). After the barcoding procedure, samples were pooled and sequenced on the NextSeq 500 Platform (Illumina) with a median (interquartile range) coverage of 17386X (8157X-27355X) (eAppendix 2 and eTable 1 in the Supplement). Subsequently, bioinformatic analyses were performed to identify the clonal pathogenic variant in each tumor sample. Annotation and interpretation of the TP53 variants were performed using dbSNP, COSMIC, ClinVar, and IARC TP53 databases. The identified somatic clonal TP53 variants were classified as pathogenic, likely pathogenic, or variant of unknown significance and mostly mapped in TP53 variant hot spots (eTable 1 in the Supplement). Detailed description of the experimental protocols and bioinformatic pipelines are reported in the eAppendix 2 in the Supplement.

The clonal pathogenic TP53 variants identified by the NGS approach in the tumor biopsy were then orthogonally validated in the patient’s tumor biopsy and were investigated in matched Papanicolaou tests by droplet digital polymerase chain reaction (ddPCR) experiments as detailed in eAppendix 3 in the Supplement. Briefly, for each TP53 somatic variant, a locus-specific ddPCR variant assay was designed according to the online BioRad tool (eTable 3 in the Supplement), and the limit of detection of each assay was experimentally evaluated by serial dilution experiments. Experiments were performed on a QX200 ddPCR system (BioRad) with the support of QX200 AutoDG Droplet Digital PCR System (BioRad). To reduce interexperiment and intraexperiment droplet generation variability, ddPCR analysis was run on DNA extracted from patients’ Papanicolaou test slides; matched tumor DNA, as positive control; DNA extracted from matched blood sample, as negative control; and DNA purified from healthy women’s Papanicolaou tests to assess the specificity of the assays. To this end, Papanicolaou tests from healthy women without personal history or genetic predisposition for hereditary cancers were included in the study. Selected women underwent surgery for benign conditions and Papanicolaou tests were collected at the time of surgery.

**Statistical Analysis**

For selected continuous variables, mean and SD or median and interquartile range values and their corresponding measures of dispersion were provided. Statistical analyses were carried out with GraphPad Prism, version 8.4.2 (GraphPad).

**Results**

The Figure depicts the selection of HGS-EOC patients enrolled in the study, while Table 1 details the main clinical and pathological features for each patient, as well as the number and the temporal windows before the diagnosis at which each Papanicolaou test was withdrawn. Briefly, 17 patients with histologically confirmed diagnosis of HGS-EOC (International Federation of Gynecology and Obstetrics stage II-IV) who underwent debulking surgical treatment at the Department of Obstetrics and Gynecology of San Gerardo Hospital were retrospectively selected for this study. The median (interquartile range) age at diagnosis was 60 (53-69) years (Table 1). The prevalence of BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) germline variants was 58.8% (10 patients): 8 patients carried a BRCA1 variant and 2 patients carried a BRCA2 variant (Table 1).

A total of 22 Papanicolaou test samples performed up to approximately 6 years before HGS-EOC diagnosis were collected. For 4 patients (23.5%) more than 1 Papanicolaou test sample was available for analysis; among these, 3 patients provided 2 Papanicolaou test samples, while 3 Papanicolaou test samples were available for 1 patient only. The median (interquartile range) interval from Papanicolaou test collection to HGS-EOC diagnosis was 14.9 (3.4-35.9) months.
Analysis of the somatic single nucleotide variants in the exonic regions of the TP53 gene by NGS technology allowed identification of the clonal TP53 variant in primary tumor samples of each patient. The complete list of identified variants with their allelic frequency is shown in Table 2, and further details are presented in eTable 1 in the Supplement.

For each patient, we investigated the presence of TP53 clonal variants by ddPCR technique in DNA purified from matched Papanicolaou tests samples obtained months or years before diagnosis. Since we aimed to detect variants with very low allelic frequency, the relative abundance (RA)

| Patient IDa | FIGO stage | Age at diagnosis, y | Date of primary surgical treatment, y | Germline status of BRCA | Time of Papanicolaou test, mo before surgical treatmentb |
|-------------|------------|---------------------|--------------------------------------|-------------------------|-----------------------------------------------|
| 21561       | IIIC       | 60                  | 2016                                 | WT                      | 0.2, NA, 25, 49                               |
| 21585       | IIA        | 42                  | 2017                                 | BRCA1, NA               | 11.3, NA, NA, NA                               |
| 21567       | IIIC       | 48                  | 2016                                 | BRCA1, NA               | 3, NA, NA, NA                                 |
| 21587       | IVA        | 65                  | 2017                                 | WT                      | 2, NA, NA, NA                                 |
| 21586       | IIIB       | 72                  | 2017                                 | BRCA1, NA               | 19.3, NA, NA                                 |
| 21569       | IIIC       | 81                  | 2016                                 | WT                      | 5.2, NA, NA, NA                               |
| 21624       | IIIC       | 69                  | 2017                                 | WT                      | NA, NA, 37.5, 65.3                            |
| 21570       | IIIC       | 70                  | 2016                                 | WT                      | 0.3, NA, NA, NA                               |
| 21627       | IIIC       | 54                  | 2017                                 | BRCA2, NA               | 0.7, NA, NA, NA                               |
| 21640       | IVA        | 53                  | 2018                                 | WT                      | NA, 8, NA, NA                                 |
| 21507       | IIIC       | 57                  | 2015                                 | BRCA1, NA               | 9.2, NA, NA                                  |
| 21635       | IIIC       | 60                  | 2018                                 | BRCA2, NA               | 1.3, NA, NA                                  |
| 21549       | IIIC       | 70                  | 2016                                 | BRCA1, NA               | NA, NA, 31.2, 65.3                            |
| 21521       | IIIB       | 61                  | 2016                                 | BRCA1, NA               | NA, NA, 26.7, 67.3                            |
| 21654       | IIIC       | 59                  | 2018                                 | BRCA1, NA               | 4.7, NA, NA                                  |
| 21665       | IIIC       | 47                  | 2019                                 | BRCA1, NA               | NA, NA, 37.6, NA                              |
| 21683       | IVC        | 53                  | 2018                                 | WT                      | NA, 18.5, NA, NA                              |

Abbreviations: BRCA1, presence of a germline pathogenic variant in BRCA1; BRCA2, presence of a germline pathogenic variant in BRCA2; FIGO, International Federation of Gynecology and Obstetrics; NA, not available; T, time point; WT, wild-type.

For anonymity, individual patients are identified by number.

Table 2. List of TP53 Clonal Variants Identified in Primary Tumor Biopsies

| Patient IDa | TP53 variant | Significance | In variant hot spot | NGS variant fraction, % | ddPCR relative abundance, % |
|-------------|---------------|--------------|---------------------|-------------------------|-------------------------------|
| 21561       | c.818G>A p.R273H | P            | Yes                 | 65.01                   | 69.91                         |
| 21585       | c.817C>T p.R273C | VUS          | Yes                 | 40.94                   | 44.63                         |
| 21567       | c.281C>A p.S94*  | NR           | No                  | 71.98                   | 69.51                         |
| 21587       | c.469G>T p.V157F | LP           | Yes                 | 15.12                   | 15.55                         |
| 21586       | c.818G>A p.R273H | P            | Yes                 | 79.73                   | 82.97                         |
| 21659       | c.574C>T p.Q192* | P            | Yes                 | 62.36                   | 64.10                         |
| 21624       | c.820G>T p.V274F | LP           | Yes                 | 86.72                   | 93.37                         |
| 21570       | c.844C>T p.R282W | P            | Yes                 | 89.19                   | 90.94                         |
| 21627       | c.425_427del p.P142_V143del_insL | NR | NR                  | 76.04                   | 80.92                         |
| 21640       | c.993 + 2T>G   | NR           | No                  | 70.68                   | 70.67                         |
| 21507       | c.1025G>C p.R342P | P            | Yes                 | 91.23                   | 93.75                         |
| 21635       | c.844C>T p.R282W | P            | Yes                 | 66.24                   | 65.98                         |
| 21549       | c.393_395del p.N131del | VUS | Yes                  | 54.06                   | 67.01                         |
| 21521       | c.722 C>G p.S241C | LP           | Yes                 | 61.15                   | 69.22                         |
| 21654       | c.586 C>T p.R196* | P            | Yes                 | 49.35                   | 34.03                         |
| 21665       | c.393_395del p.N131del | VUS | Yes                  | 45.34                   | 55.05                         |
| 21683       | c.602 T > A p.L201* | NR | No                  | 33.42                   | 35.22                         |

Abbreviations: ddPCR, droplet digital polymerase chain reaction; LP, likely pathogenic; NGS, next generation sequencing; NR, not reported; P, pathogenic; VUS, variant of unknown significance.

For anonymity, individual patients are identified by number.
percentage of the analyzed TP53 variant was calculated according to 2 stringent parameters: only droplets containing DNA harboring TP53 variants marked by the fluorescein fluorophore were considered positive and each sample had to show fluorescein-marked droplets in all independent replicates, otherwise results were considered irreproducible artifacts (eAppendix 3 in the Supplement). Based on results from serial dilution sensitivity tests (eTable 2 in the Supplement), all ddPCR assays but 1 (ie, TP53 c.469G>T) were able to detect approximately 0.1% to 0.05% of tumor content with variable RA, depending on the starting tumor variated allele frequency. The assay for TP53 c.817C>T allowed detection down to 0.01% (eTable 2 in the Supplement). Eleven Papanicolaou tests from healthy women were analyzed as negative controls using the equivalent DNA source, to assess assay specificity. None of these samples was positive for TP53 variants identified in our tumor cohort (eTable 3 in the Supplement).

For 11 of 17 patients (64%), the TP53 clonal variant was also detectable in all matched Papanicolaou tests collected within 6 months before diagnosis (Time point [T] 1) or earlier (T2, T3, and T4) (Table 3). The RA percentages were always higher than the limit of detection established by the sensitivity tests. For 3 patients, 2 or more Papanicolaou tests conducted at different times before diagnoses were available (Table 1). For 1 patient, the TP53 clonal variant was identified in all 3 Papanicolaou tests, performed 9 days (T1, RA = 0.24%), 25 months (T3, RA = 0.21%), and 49 months (T4, RA = 0.26%) prior to diagnosis (Table 3). Among 2 patients with 2 samples each, the TP53 variant was confirmed 27 months (T3, RA = 0.05%) and 68 months (T4, RA = 0.07%) before diagnosis for 1 patient and in only 1 of the available Papanicolaou tests for the other patient (T3, RA = 0.04%) (Table 3).

Discussion

This cohort study found that TP53 clonal somatic variants found at the ovarian cancer site were detectable in the same patients’ archival Papanicolaou tests performed up to 6 years before tumor diagnosis. Remarkably, for 2 of 3 patients for whom 2 or more archival Papanicolaou tests were available, the same clonal TP53 variant was confirmed in all samples. Moreover, although most of the TP53 variants were located in variant hot spots, they were not found in healthy women’s samples, corroborating the etiopathogenetic role of selected TP53 variants in patients with HGS-EOC. To our

| Patient ID  | TP53 variant | Papanicolaou tests, % relative abundance |
|-------------|--------------|------------------------------------------|
| 21561       | c.818G>A p.R273H | 0.24 NA 0.21 0.26 |
| 21585       | c.817C>T p.R273C | NA 0.21 NA NA |
| 21567       | c.281C>A p.S94* | 0.07 NA NA NA |
| 21587       | c.469G>T p.V157F | ND NA NA NA |
| 21586       | c.818G>A p.R273H | NA 0.15 NA NA |
| 21569       | c.574C>T p.Q192* | 1.18 NA NA NA |
| 21624       | c.820G>T p.V274F | NA NA 0.04 ND |
| 21570       | c.844C>T p.R282W | 2.62 NA NA NA |
| 21627       | c.425_427del p.P142_V143del_insL | 2.4 NA NA NA |
| 21640       | c.993 + 2T>G | NA ND NA ND |
| 21507       | c.1025G>C p.R342P | NA 9.2 NA NA |
| 21635       | c.844C>T p.R282W | ND NA NA NA |
| 21549       | c.393_395del p.N131del | NA NA ND ND |
| 21521       | c.722 C>G p.S241C | NA NA 0.05 0.07 |
| 21654       | c.586 C>T p.R196* | 0.09 NA NA NA |
| 21665       | c.393_395del p.N131del | NA NA ND NA |
| 21683       | c.602 t>A p.L201* | NA 0.06 NA NA |

Abbreviations: NA, not available; ND, not detected.

a For anonymity, individual patients are identified by number.

b Time points are arbitrary temporal windows used to describe the time before diagnosis at which each Papanicolaou tests was available. T1 indicates 0 to 6 months; T2, 7 to 24 months; T3, 25 to 48 months; T4, 49 months or longer.
knowledge, this is the first experimental evidence that supports the mathematical model according to which HGS-EOC takes at least approximately 6 years to develop. Considering the anatomical continuity between tubal lumen and cervical canal, it is plausible that cytological material could be a useful biological material to detect biomarkers associated with HGS-EOC many years before diagnosis, although a study focused on HGS-EOC etiopathogenesis is necessary to assess the viability of this model.

The detectability of TP53 clonal variants in Papanicolaou test samples taken at the time of ovarian cancer diagnosis has been shown previously. A 2019 study by Arildsen et al reported that TP53 variants detected by ddPCR were found in 7 diagnostic liquid-based Papanicolaou tests from 15 HGS-EOCs. Arildsen et al detected TP53 clonal variant in 1 patient's Papanicolaou test performed 20 months before diagnosis. The discrepancy between these findings and our results is possibly due to technical issues, such as the likelihood that the DNA stability in liquid-based archival Papanicolaou tests was lower than that of our samples, which were brush-based and stored dry. These data suggest that it is possible to use the Papanicolaou test for early diagnosis of HGS-EOC.

Strengths and Limitations
This study has 2 main strengths. To our knowledge, this is the first investigation in which Papanicolaou tests from healthy women were used as controls to investigate the presence of TP53 variants in the same biological material analyzed in patients with HGS-EOC. The absence in the control samples of the TP53 variants identified in tumor DNA supports our hypothesis that the presence of these TP53 variants in patients' archival Papanicolaou test samples represents an early sign of disease. Additionally, despite stringent application of ddPCR analysis criteria to limit the inclusion of potentially false-positive results, we obtained a detection rate close to 64%.

This study also has limitations. The main limitations of the study are that it is a proof-of-principle study, conducted in a small cohort of patients with Papanicolaou tests collected at different time points for each patient and with a low degree of overlap among patients. Indeed, the retrieval of the material for this study was difficult, as Papanicolaou test screening was based on women's voluntary participation, and Papanicolaou tests were usually conducted in different laboratories during the course of the study. Secondly, in 5 of 17 patients, Papanicolaou test results were negative for the TP53 variants. For 1 patient with 2 Papanicolaou tests available, the TP53 variant was detected in only 1 Papanicolaou test. Thus, the detection rate was calculated only on 11 patients with all Papanicolaou tests positive for TP53 variants. Since the archival Papanicolaou test material was not originally meant to be used for DNA analysis, sampling procedures and storage conditions could have interfered with DNA quality. Indeed, the quality of DNA from the healthy controls, processed immediately after administration, was superior (efigure in the Supplement). Therefore, it is conceivable that the negative findings for TP53 variants are, at least in part, due to inadequate sample collection and storage. Another limitation worth noting is that we evaluated only tumor-matched TP53 clonal variants. Somatic evolution in nonneoplastic tissues implies that, owing to aging or other physiological processes, multiple somatic variants are normally present ubiquitously at the mosaic level. Therefore, prospective clinical studies conceived and designed on large populations of women are required to validate our findings.

Conclusions
This cohort study found specific variants in multiple Papanicolaou tests from the same patients conducted up to 6 years before the diagnosis of HGS-EOC. The identified variants were mostly located in variant hot spots. The development of a clinically and analytically accurate diagnostic test will require a large, longitudinal prospective study to be conducted with appropriate numbers of patients and healthy controls using standardized sampling procedures and highly sensitive NGS-based approaches to monitor the entire TP53 gene. Women harboring BRCA1 or BRCA2 germinal variants could be suitable candidates to be recruited into such a study, given their high risk of
HGS-EOC and their intensive monitoring. Furthermore, only such ad hoc studies will ultimately allow a robust evaluation as to whether this early diagnostic approach might translate into survival benefits. Our results hint at a promising prospect to significantly improve the future diagnosis of HGS-EOC, thus increasing its potential curability.

ARTICLE INFORMATION
Accepted for Publication: April 6, 2020.
Published: July 1, 2020. doi:10.1001/jamanetworkopen.2020.7566
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Paracchini L et al. JAMA Network Open.

Corresponding Author: Maurizio D’Incalci, MD, Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Mario Negri 2, 20156, Milan, Italy (maurizio.dincalci@marionegri.it).

Author Affiliations: Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy (Paracchini, Pesenti, Beltrame, Bosetti, D’Incalci, Marchini); Department of Obstetrics and Gynecology, Università degli Studi Milano-Bicocca, San Gerardo Hospital, Monza, Italy (Delle Marchette, Bianchi, Grassi, Buda, Landoni, Paderno, Adorni, Vicini, Fruscio); Department of Obstetrics and Gynecology, Azienda Socio Sanitaria Territoriale -Monza, Desio Hospital, Desio, Italy (Ceppi); Department of Pathology, Università degli Studi Milano-Bicocca, San Gerardo Hospital, Monza, Italy (Perego, Leone).

Author Contributions: Drs Marchini and D’Incalci had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Paracchini and Pesenti contributed equally to this study. Drs Marchini and Fruscio are co-last authors.

Concept and design: Paracchini, Pesenti, Delle Marchette, Beltrame, Bianchi, Landoni, Ceppi, D’Incalci, Marchini, Fruscio.

Acquisition, analysis, or interpretation of data: Paracchini, Pesenti, Delle Marchette, Beltrame, Bianchi, Grassi, Buda, Ceppi, Bosetti, Paderno, Adorni, Vicini, Perego, Leone, Marchini, Fruscio.

Drafting of the manuscript: Paracchini, Pesenti, Beltrame, Landoni, Paderno, Vicini, Leone.

Critical revision of the manuscript for important intellectual content: Paracchini, Pesenti, Delle Marchette, Beltrame, Bianchi, Grassi, Buda, Landoni, Ceppi, Bosetti, Adorni, Perego, D’Incalci, Marchini, Fruscio.

Statistical analysis: Pesenti, Beltrame, Bosetti.

Obtained funding: D’Incalci.

Administrative, technical, or material support: Paracchini, Delle Marchette, Bianchi, Grassi, Perego, Leone, Marchini.

Supervision: Paracchini, Buda, Landoni, Leone, D’Incalci, Marchini, Fruscio.

Conflict of Interest Disclosures: Drs Paracchini and Pesenti reported receiving grant fellowships from Italian Association for Cancer Research. Dr Beltrame reported receiving personal fees from Eli Lilly outside the submitted work. No other disclosures were reported.

Funding/Support: Support for this study was provided by the Alessandra Bono Foundation, the Italian Association for Cancer Research (grant No. 19997: Dr Marchini), and the Nerina and Mario Mattioli Foundation.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Andreas Gescher (University of Leicester, Leicester, UK) provided critical revision and editing of the manuscript and Giulia Siravegna, PhD (Harvard Medical School, Boston, Massachusetts) provided critical discussion of droplet digital polymerase chain reaction data. They were not compensated for their work.

REFERENCES
1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474 (7353):609-615. doi:10.1038/nature10166
2. Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016;35(1):48-55. doi:10.1097/PGP.0000000000000207
3. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. *Nat Commun.* 2017;8(1):1093. doi:10.1038/s41467-017-00962-1

4. Soong TR, Howitt BE, Miron A, et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. *J Pathol.* 2018;246(3):344-351. doi:10.1002/path.5145

5. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. *Sci Transl Med.* 2013;5(167):167ra4. doi:10.1126/scitranslmed.3004952

6. Erickson BK, Kinde I, Dobbin ZC, et al. Detection of somatic *TP53* mutations in tampons of patients with high-grade serous ovarian cancer. *Obstet Gynecol.* 2014;124(5):881-885. doi:10.1097/AOG.0000000000000484

7. Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Sci Transl Med.* 2018;10(433):eaap8793. doi:10.1126/scitranslmed.aap8793

8. National Center for Biotechnology Information. dbSNP. Accessed May 29, 2020. https://www.ncbi.nlm.nih.gov/snp/

9. Catalog of Somatic Mutations in Cancer. Accessed May 29, 2020. https://cancer.sanger.ac.uk/cosmic

10. National Center for Biotechnology Information. ClinVar. Accessed May 29, 2020. https://www.ncbi.nlm.nih.gov/clinvar/

11. World Health Organization. IARC TP53 Database. Accessed May 29, 2020. https://p53.iarc.fr/

12. Chang MT, Bhattacharj, Schram AM, et al. Accelerating discovery of functional mutant alleles in cancer. *Cancer Discov.* 2018;8(2):174-183. doi:10.1158/2159-8290.CD-17-0321

13. Arildsen NS, Martin de la Fuente L, Måsbäck A, et al. Detecting *TP53* mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. *Sci Rep.* 2019;9(1):15506. doi:10.1038/s41598-019-51697-6

14. Yizhak K, Aguet F, Kim J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. *Science.* 2019;364(6444):eaaw0726. doi:10.1126/science.aaw0726

15. Krimmel-Morrison JD, Ghelzelaygh TS, Lian S, et al. Characterization of *TP53* mutations in PAP test DNA of women with and without serous ovarian carcinoma. *Gynecol Oncol.* 2020;156(2):407-414. doi:10.1016/j.ygyno.2019.11.124

**SUPPLEMENT.**

eAppendix 1. DNA Extraction

eFigure. Distribution of DNA Concentration From Tumor FFPE Samples, Blood Samples, and Papanicolaou Tests From Patients and Healthy Women

eAppendix 2. Tumor Next Generation Sequencing

eTable 1. Summary Description of *TP53* Clonal Somatic Variants Identified by Next Generation Sequencing

eAppendix 3. Droplet Digital Polymerase Chain Reaction Experiments

eTable 2. Serial Dilutions Experiments

eTable 3. Assay Specificity

eReferences